The tweet was deleted by the author.
But we saved everything 🙂.
Capricor Therapeutics, Inc. CEO Linda Marbán participated in the Oppenheimer CNS and NeuroMuscular Summit held in Miami, Florida.
She joined industry leaders from Sarepta and Dyne on the panel titled “Advancing Duchenne: Perspectives From Industry Leaders,” which focused on developments and strategies shaping the future of therapies for Duchenne muscular dystrophy. The event brought together prominent firms working in the field, reflecting the sector's growing attention to innovation and partnerships. Capricor Therapeutics, Inc. reiterated its commitment to advancing discussions around treatment and collaborative industry progress.
Earlier this year, Capricor Therapeutics presented new research on muscle preservation and regeneration at the CureDuchenne FUTURES Conference in Orlando. The company also reported its first quarter 2026 financial results and issued a corporate update for investors following its latest earnings release. These developments reflect Capricor's ongoing engagement with both the scientific community and stakeholders.